Olanzapine – Kodiac biolabs

Plain-language summaryIntrigue 64 / 100

Olanzapine (Zyprexa) is the closest pharmacological cousin of clozapine, brought to market by Eli Lilly in 1996 specifically to capture clozapine’s effectiveness without its agranulocytosis risk. That worked: olanzapine is reliably one of the more effective antipsychotics for schizophrenia and acute mania, and patients do not need weekly blood draws. The trade-off is the worst metabolic profile of any drug in its class. Patients on olanzapine routinely gain 10 to 30 pounds, develop dyslipidemia, and progress to type 2 diabetes at high rates. Used for schizophrenia, acute mania, and treatment-resistant depression in combination with fluoxetine (the Symbyax product). The recent intramuscular long-acting injection (Zyprexa Relprevv) carries an unusual risk of post-injection delirium and sedation. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

50/100

Mature reference atypical antipsychotic with settled science and minimal frontier research value

Look, the compound’s story begins and essentially ends in 1996, when Eli Lilly got FDA approval for Zyprexa. Thats almost thirty years of data, which is simultaneously olanzapine’s greatest asset and its most damning liability as a research target. The evidence base is unimpeachable. CATIE, multiple phase 3 head-to-heads, decades of real-world pharmacovigilance across millions of patients: if you want to know what olanzapine does, the literature tells you with unusual clarity. This is not a compound with ambiguous effects or contested mechanisms.

The receptor profile is genuinely broad and worth understanding in structural terms. D2 (Ki approximately 11 nM), 5-HT2A (Ki approximately 4 nM), H1 (Ki approximately 0.087 nM, among the tightest H1 affinities in clinical antipsychotic use), plus alpha-1, muscarinic, and multiple serotonin subtypes. That H1 affinity is the most pharmacologically interesting feature: combined H1 and 5-HT2C antagonism produces a metabolic syndrome signature that is the worst of any commonly used antipsychotic, with mean weight gain of 4 to 12 kg over 12 weeks and incident type 2 diabetes well-documented. If your research program is specifically interrogating hypothalamic H1/5-HT2C co-blockade as a driver of metabolic dysregulation, olanzapine is a legitimate and well-characterized probe for that question.

The structural comparison with clozapine also has real value for SAR work. Olanzapine is essentially clozapine with a thieno ring substitution that eliminates the agranulocytosis liability while preserving the broad-spectrum atypical pharmacology. For investigators studying what the clozapine scaffold actually buys you mechanistically, comparing these two compounds is worth pulling apart carefully. Clozapine remains the efficacy gold standard in treatment-resistant schizophrenia; olanzapine is the closest approximation you can study without REMS infrastructure.

What we don’t like: the novelty is gone. The mechanism of atypical antipsychotic action via D2/5-HT2A ratio modulation is settled territory, worked out through the 1990s and confirmed repeatedly since. Theres no fresh frontier here, no emerging indication driving genuine bench excitement, no mechanistic surprise hiding in the data. The compound functions as a reference comparator in clinical trials precisely because it is established science, and that same quality makes it a low-priority target for investigators trying to do something new.

The most active current research angle is low-dose antiemetic use, particularly as a triplet-regimen adjunct for chemotherapy-induced nausea and vomiting. That’s real, has plausible mechanistic support via 5-HT3 and 5-HT2 blockade, and ASCO guidelines now reflect it. But it’s an adjacent application of settled pharmacology, not a discovery. We stock olanzapine as a reference compound. For a CNS pharmacology program that needs a canonical broad-spectrum atypical for mechanistic comparison or metabolic interrogation, it earns its place on the shelf. For investigators hunting genuinely fresh targets, the literature here is already written.

Novelty: 18
Mechanism promise: 32
In-category differentiation: 48
Evidence quality: 85
Translational signal: 80
Research bench value: 55

Rationale Olanzapine scores high on evidence and translational signal because it is an FDA-approved drug with three decades of replicated clinical data, but both novelty and mechanism promise are low: the D2/5-HT2A atypical pharmacology story has been understood since the clozapine era, and there is no emerging indication or mechanistic surprise driving serious bench interest. Bench value is moderate because it functions as a canonical reference compound and a legitimate probe for H1/5-HT2C-driven metabolic effects.

Atypical antipsychotic

A thienobenzodiazepine atypical antipsychotic structurally and mechanistically related to clozapine, without the agranulocytosis risk.

Abstract

Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; CAS 132539-06-1; molecular formula C17H20N4S; molecular weight 312.43) is a thienobenzodiazepine atypical antipsychotic developed at Eli Lilly and approved by the FDA in 1996 under the trade name Zyprexa. The receptor profile is closely related to clozapine: D2 (Ki approximately 11 nM, higher affinity than clozapine), 5-HT2A (Ki approximately 4 nM), H1 (Ki approximately 0.087 nM, among the most potent in clinical use), alpha-1, muscarinic, 5-HT2C, 5-HT3, 5-HT6, 5-HT7. The structural difference from clozapine eliminates the agranulocytosis liability while preserving the broad-spectrum atypical pharmacology. Plasma half-life is 21 to 54 hours; metabolism is via CYP1A2 and direct glucuronidation. The compound carries the highest metabolic risk profile of any commonly used antipsychotic: dyslipidemia, weight gain (mean 4 to 12 kg over 12 weeks), and incident type 2 diabetes are well-documented, attributed to combined H1 and 5-HT2C antagonism. Approved for schizophrenia, bipolar I disorder, and treatment-resistant depression in combination with fluoxetine (Symbyax). Used as a reference broad-spectrum atypical antipsychotic.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-234Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.